Adoptive Cell Therapy and new approaches against cancer development

• Leyla M. Sánchez Palancar ^[1] ; Beatriz Ren Barroso ^[1] ; Aida María Cañete Navarro ^[1] ; Guadalupe Estrella Guisado ^[1]
  1. [1] Universidad Pablo de Olavide

     Universidad Pablo de Olavide

     Sevilla, España

     
• Localización: MoleQla: revista de Ciencias de la Universidad Pablo de Olavide, ISSN-e 2173-0903, Nº. 47, 2023
• Idioma: inglés
• Enlaces
  • Texto Completo Ejemplar
• Resumen

  • The immune system plays an essential role in the development and growth of many cancer types. Therefore, immunotherapeutic strategies have been developed in recent years. Adoptive cell therapy (ACT), also known as cellular immunotherapy, is a treatment that consists of using the cells of our immune system to eliminate cancer. Approaches based on ACT usually involve the use of tumor-infiltrating lymphocytes (TIL), chimeric antigen receptors (CAR), or gene-modified T cells expressing novel T cell receptors (TCR) as new strategies to modify the immune system to recognize tumor cells and exert antitumor effector functions. These treatments have shown promising results in various tumor types, and multiple clinical trials are being conducted for their further optimization. This review provides an overview of the developments in ACT and its future potential in cancer treatment, focusing mainly on CAR T cell and TCR therapy.